Drug intelligence / Profile preview

expanded unmodified autologous CD4+ T cells

Development stage: Preclinical
Modality: Cell Therapies
Administration: Intravenous

Overview

Expanded unmodified autologous CD4+ T cells are a form of adoptive cell therapy where CD4+ T cells are harvested from a patient, expanded ex vivo (outside the body) with stimulatory factors like IL-2 and/or anti-CD3/CD28 antibodies, and then reinfused back into the same patient. Unlike CAR-T or TCR-modified T cells, these cells are not genetically engineered. CD4+ T cells can provide helper functions for CD8+ T cells and may also develop cytotoxic capabilities against tumor cells.

Targets

pMHC-II (Peptide-major histocompatibility complex class II complex)

Beyond the preview

Go deeper on expanded unmodified autologous CD4+ T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on expanded unmodified autologous CD4+ T cells.

Explore the full profile